Antigenics slashes staff in bid to conserve cash

Antigenics is slashing one-third of its staff and focusing on its "highest potential products" in a bid to fashion a successful new drug development strategy while conserving cash. The New York-based biotech says that it will eliminate approximately 81 jobs. Data analysis for its Oncophage kidney cancer trial should be completed in March of 2006. "We have elected to take decisive and prudent actions now in order to preserve our cash and position the company to maximize the full value of our diverse portfolio," said Garo H. Armen, Ph.D., chairman and CEO of Antigenics.

- read this release for more information

Suggested Articles

When it’s time to go public, most biotech companies for the Nasdaq. Not so for SQZ Biotech, which raised $71 million in its NYSE debut.

The saga of COVID antibody R&D continues as the REGN-COV2 antibody cocktail used by President Donald Trump has been hit by safety concerns.

A Dartmouth-led team proposed a method for targeting and inhibiting the most aggressive cells in breast tumors to improve responses to chemotherapy.